Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Sareum Holdings PLC raises funds

The proceeds will be used to advance the company drug development programme
Cash
The company has raised £1.1mln

Cancer drug discovery and development firm Sareum Holdings Plc (LON:SAR) has raised around £1.1mln by placing shares at 0.7p each.

The proceeds will be used to advance the company drug development programme, and for general working purposes.

After issuing 157.8mln shares, the company now has 2.65bn shares in issue.

Hybridan, joint-broker to the company, said Sareum is “now in an even stronger place going forward” as their lead product Checkpoint Kinase 1 is due to begin Phase I trials by H1 2016. 

“We believe the monies raised will put the company in a better position when they talk to potential licensing partners whilst at the same time enable them to rapidly develop their other pre-clinical programmes,” Hybridan said.

Sareum shares closed at a mid-market price of 0.815p last night; as usually happens when share issues announced, the share price has moved towards the issue price, with Sareum shares trading at 0.618p in the lunchtime trading session.

John-H.jpg
Why Invest In Sareum Holdings Plc? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile

Sareum Holdings Plc Timeline

Newswire
May 17 2016
Newswire
February 01 2016

Related Articles

Knee surgery
July 13 2016
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
shutterstock_327930536.jpg
May 19 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.